Royalty Pharma plc 2.2% 02-SEP-2030Royalty Pharma plc 2.2% 02-SEP-2030Royalty Pharma plc 2.2% 02-SEP-2030

Royalty Pharma plc 2.2% 02-SEP-2030

No trades
See on Supercharts

Key terms


Outstanding amount
‪3.19 M‬USD
Face value
1,000.00USD
Minimum denomination
2,000.00USD
Coupon
2.20% (Fixed)
Coupon frequency
Semi-annual
Yield to maturity
2.43%
Maturity date
Sep 2, 2030
Term to maturity
5 years

About Royalty Pharma plc 2.2% 02-SEP-2030


Sector
Health Technology
Issue date
Sep 2, 2020
FIGI
BBG00WXWTPG8
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.